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This Journal feature begins with a case vignette highlighting a common clinical problem. 
Evidence supporting various strategies is then presented, followed by a review of formal guidelines,  
when they exist. The article ends with the authors’ clinical recommendations. 
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available at 
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An otherwise healthy 55-year-old man reports that he has been itchy all over for 
6 months. The itch interferes with falling asleep and wakes him repeatedly during 
the night. Initially, there was no rash, but during the past 4 months, itchy nodules and 
plaques have developed on his back, arms, and legs. Treatment with sedating and 
nonsedating oral antihistamines and topical glucocorticoids has had no effect. How 
would you evaluate and manage this case?
The Clinic a l Problem
Chronic pruritus, which is defined as itch persisting for more than 6 weeks,1 is 
common. It may involve the entire skin (generalized pruritus) or only particular 
areas, such as the scalp, upper back, arms, or groin (localized pruritus). The inci-
dence of chronic pruritus increases with age.2,3 The condition is more common in 
women than in men and is diagnosed more frequently in Asians than in whites.4,5 
Chronic pruritus is associated with a markedly reduced quality of life. In a recent 
study, chronic itch was shown to be as debilitating as chronic pain.6 Deranged sleep 
patterns and mood disturbances, including anxiety and depression, are common 
and may exacerbate the itching.7-11
Chronic pruritus is characteristic of several dermatologic diseases (e.g., atopic 
eczema, psoriasis, lichen planus, and scabies) but also occurs in a variety of non-
cutaneous disorders. The causes of chronic pruritus can be broadly categorized into 
four major groups1,12: dermatologic causes, systemic causes (e.g., cholestasis, chron-
ic kidney disease, myeloproliferative disorders, and hyperthyroidism), neuropathic 
causes (e.g., notalgia paresthetica [a distinctive itch of the upper back] and brachio-
radial pruritus [a characteristic itch of the arms, probably caused by spinal-nerve 
impingement13,14]), and psychogenic causes. Itching of any type may elicit second-
ary skin changes as a result of scratching, rubbing, and picking, so the presence 
of skin findings does not rule out a systemic cause. Excoriation and nonspecific 
dermatitis can camouflage both cutaneous and noncutaneous causes of itch. In 
some cases, the underlying cause is unclear (pruritus of undetermined origin).
The mechanisms underlying the various types of chronic pruritus are complex. 
A number of mediators are involved in the itch sensation (Fig. 1). The itch signal 
is transmitted mainly by small, itch-selective unmyelinated C fibers originating in 
the skin. Histamine-triggered neurons and nonhistaminergic neurons may be in-
volved. They form a synapse with secondary neurons that cross over to the contra-
lateral spinothalamic tract and ascend to multiple brain areas involved in sensa-
tion, evaluative processes, emotion, reward, and memory. These areas overlap with 
those activated by pain.15,16 Patients with chronic itch often have peripheral as well 
as central neural hypersensitization. In this state, sensitized itch fibers overreact 
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to noxious stimuli that usually inhibit itch, such 
as heat and scratching. Misinterpretation of non-
noxious stimuli also occurs: touch may be per-
ceived as itch.17 It is not unusual for patients to 
report that just taking off or putting on their 
bedclothes triggers a bout of itching. Strange 
symptoms like this, combined with the extreme 
distress of chronic itch, sleep loss, and visits to 
many physicians, may lead to the erroneous di-
agnosis of psychogenic itch.
S tr ategies a nd E v idence
Evaluation
The first step in the evaluation of chronic pruri-
tus is to determine whether the itch can be at-
tributed to a dermatologic disease or whether an 
underlying noncutaneous cause is present. The 
evaluation should start with medical history tak-
ing and physical examination. A detailed review 
of systems (with attention to constitutional symp-
toms that may point to an underlying systemic 
illness18) should be performed and a thorough 
drug history (with attention to agents that cause 
itch, such as opioid analgesics) obtained. Such a 
review should be repeated at follow-up visits if the 
diagnosis remains elusive; pruritus is sometimes 
the first manifestation of a systemic disease, such 
as Hodgkin’s disease or primary biliary cirrhosis, 
antedating other symptoms by months.
The skin should be examined carefully for pri-
mary lesions. Excoriations, nonspecific dermatitis, 
prurigo nodularis, and lichen simplex chronicus 
are secondary lesions for which an underlying 
cause should be sought (Fig. 2). In some patients 
— for example, those with scabies, pemphigoid, 
or dermatitis herpetiformis — subtle primary 
lesions may be masked by secondary changes or 
may be nondiagnostic (e.g., patients with scabies 
may present with urticarial features, scattered sec-
ondary patches of dermatitis, nodules on genitalia, 
and interdigital dermatitis). Patients with exces-
sively dry skin (xerosis) usually present with mini-
mally detectable changes, but erythematous and 
scaly inflammatory patches may develop.
In addition to a history taking and physical 
examination, screening laboratory and imaging 
studies are suggested (Fig. 3).
Management
Treatment of chronic pruritus should be directed 
at the underlying cause when possible. Itch that 
is caused by hyperthyroidism or cutaneous T-cell 
lymphoma, for example, resolves with effective 
treatment of these conditions. In the absence of a 
definitive diagnosis, symptomatic treatment is re-
quired. Data from randomized, controlled trials 
of agents for itch treatment are scarce, and in prac-
tice, the treatments that are used have variable 
and often suboptimal effectiveness (Table 1).19
Topical Therapy
Emollients and Soaps
For mild or localized itch and for xerosis (e.g., 
winter itch), topical emollients are the first-line 
therapy. Such agents probably reduce itch by soft-
key Clinical points
chronic pruritUs
•  Chronic pruritus (itching that persists for more than 6 weeks) may be caused by inflammatory skin diseases, systemic 
diseases, neuropathic conditions, and psychogenic disorders.
•  The presence of a rash does not necessarily indicate a primary skin disease; lichenification, prurigo nodules, patches 
of dermatitis, and excoriations result from rubbing and scratching.
•  The initial evaluation of a patient who has pruritus of undetermined origin should include a complete blood count 
with a differential count, a chest radiograph, and tests of hepatic, renal, and thyroid function. Patients with itch of 
undetermined origin should be reevaluated periodically.
•  In the initial treatment of symptoms, the use of mild cleansers, emollients, topical anesthetics, and coolants may be 
helpful.
•  Sedating antihistamines may be used, primarily to help the patient sleep.
•  Anticonvulsants, antidepressants, and mu-opioid antagonists appear to be helpful in some forms of chronic itch.
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ening the sharp edges of the outermost layer of 
dry skin (stratum corneum) and by improving skin-
barrier function. Cutaneous-barrier insufficiency 
is common in inflammatory skin diseases and is 
exacerbated by repetitive scratching, which facili-
tates the entry of irritants. “Wet pajama” treat-
ment can be helpful and soothing when extensive 
inflammation is present, as in severe atopic der-
matitis.20,21 In this technique, the patient first 
applies an emollient and a low-potency topical 
glucocorticoid to the affected area and then dips 
a pair of cotton pajamas in water, wrings them out, 
and wears them overnight. This treatment should 
be limited to short courses (≤1 week at a time) 
because of the associated risks of folliculitis and 
excess absorption of topical glucocorticoids.
Since solutions with a high pH such as alka-
line soaps increase the secretion of serine prote-
ases that may induce itch, their use should be 
avoided in favor of moisturizers and cleansers with 
a low pH (4.5 to 6.0).22 If secondary infection is 
present, it should be treated.
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Figure 1. Pathways of Itch from Skin to Brain.
Itch originates in the epidermis and dermal–epidermal junction and is transmitted by itch-selective C nerve fibers. Some of these fibers 
are sensitive to histamine, but the majority are not. A complex interplay among T cells, mast cells, neutrophils, eosinophils, keratinocytes, 
and nerve cells (along with increased release of cytokines, proteases, and neuropeptides) leads to exacerbation of itch. The C fibers form 
synapses with second-order projections in the dorsal horn, and the itch signal ascends in the contralateral spinothalamic tract, with pro-
jections to the thalamus. From the thalamus, itch is transmitted to several regions of the brain that are involved in sensation, evaluative 
processes, emotion, reward, and memory.
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Anesthetics
Capsaicin, which acts locally by desensitizing 
peripheral-nerve fibers,23 has been used as an an-
tipruritic agent in various localized disorders. In 
a randomized, vehicle-controlled trial, topical cap-
saicin showed efficacy in patients with notalgia 
parasthetica.24 Clinical experience suggests that 
higher concentrations of capsaicin (up to 0.1%) 
may be more effective than lower ones.25
Preparations of topical anesthetics such as 
pramoxine 1% or 2.5% cream and the eutectic 
mixture of lidocaine and prilocaine 2.5% cream 
have been reported in case series to have short-
term beneficial effects for neuropathic, facial, 
and anogenital itch,25 although data from ran-
domized trials that support their use are limited. 
In one randomized trial involving patients with 
pruritus caused by chronic kidney disease, pramox-
ine 1% cream significantly reduced pruritus, as 
compared with vehicle alone.26 The safety of long-
term use of these agents or use over a large area 
of skin is unknown.
Coolants
Topical menthol relieves itch by activating A-del-
ta cold afferents, which transmit the sensation of 
cold by the activation of an ion channel called 
transient receptor potential cation channel sub-
family M member 8 (TRPM8); the cool sensation 
appears to reduce itch.27 Clinical experience sug-
gests that topical menthol may be effective in 
low concentrations (1 to 5%); higher concentra-
tions tend to cause irritation.27 The long-term 
use of this agent for chronic itch has not been 
studied.
Glucocorticoids
Although topical glucocorticoids do not have di-
rect antipruritic effects, they are antiinflamatory. 
In randomized, controlled trials, glucocorticoids 
(both those of high potency and those of moder-
ate potency) have shown efficacy in inflammatory 
skin conditions, such as atopic eczema, psoriasis, 
lichen planus, and genital lichen sclerosus.25,28
Potent glucocorticoids are also used for second-
ary manifestations of chronic itch, such as pru-
rigo nodularis and lichen simplex chronicus, al-
though such therapy is largely based on clinical 
experience in the absence of controlled studies.
Other Agents
Randomized clinical trials have shown the efficacy 
of the topical calcineurin inhibitors tacrolimus 
and pimecrolimus in reducing itch in inflamma-
tory skin conditions, including seborrheic der-
matitis, psoriasis, and various types of eczema.29
In a small controlled study, tacrolimus was effec-
tive for resistant anogenital pruritus.30 The anti-
pruritic effect of these agents may be mediated 
by the activation of transient receptor potential 
cation channel subfamily V member 1 (TRPV1). A 
common adverse effect of topical calcineurin in-
hibitors is a burning sensation that fades after a 
few days of repeated applications.
In one randomized, controlled trial,31 doxepin 
5% cream, a tricyclic antidepressant with potent 
anti-H1 properties, relieved localized itch in pa-
tients with atopic eczema and contact dermatitis. 
However, efficacy has not been shown in other 
conditions that cause chronic pruritus. Potential 
adverse events include drowsiness (from absorp-
tion through the skin) and allergic contact der-
matitis.
Systemic Therapy
Antihistamines
In clinical practice, sedating antihistamines (e.g., 
hydroxyzine, doxepin, and diphenhydramine) are 
often used as first-line treatment for pruritus. 
However, data from randomized trials are lack-
ing to support the efficacy of antihistamines in 
pruritic conditions other than urticaria. It appears 
in practice that the observed benefits may be due 
to the drugs’ soporific properties, which may 
help patients sleep and take the edge off itching 
during the day. Nonsedating H1-receptor and H2-
receptor antagonists have at most a limited effect 
Figure 2. Prurigo Nodules on Lichenified Skin in a Patient 
with Chronic Pruritus.
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in the treatment of chronic itch, since histamine 
does not play a major role in conditions other 
than urticaria.25,32
Neuroactive Medications
Gabapentin and pregabalin, structural analogues 
of the neurotransmitter γ-aminobutyric acid, are 
effective for several types of pruritus. In controlled 
trials involving patients with pruritus caused by 
chronic kidney disease, low doses of gabapentin 
(100 to 300 mg three times a week) were signifi-
cantly more effective in reducing itch than pla-
cebo.33,34 Case reports have described the use of 
these drugs in practice to reduce neuropathic itch 
(e.g., postherpetic itch, brachioradial pruritus, and 
prurigo nodularis), although there are no data 
from controlled studies of these conditions.15,35
The mechanisms of action are unclear. The most 
frequent adverse effects are constipation, weight 
gain, drowsiness, ataxia, and blurred vision.
Antidepressants
Selective serotonin-reuptake inhibitors (e.g., par-
oxetine, sertraline, fluvoxamine, and fluoxetine) 
have been reported to reduce generalized pruri-
tus of various types, including but not limited to 
psychogenic itch, in case series.36 One small ran-
domized trial showed a modest antipruritic ef-
fect of paroxetine, as compared with placebo.37 A 
small double-blind trial demonstrated the effi-
cacy of sertraline (at a daily dose of 100 mg) for 
cholestatic itch.38 Case reports have also sug-
gested that the oral noradrenergic and specific 
serotonergic antidepressant mirtazapine (at a dai-
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Figure 3. Diagnostic Workup for Chronic Pruritus.
HIV denotes human immunodeficiency virus.
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ly dose of 15 mg) may relieve nocturnal itch of 
various types, including cancer-related itching.39,40 
Improvement in intractable itch has been reported 
in a case series of patients with cutaneous T-cell 
lymphoma who were treated with a combination 
of low-dose mirtazapine and gabapentin or pre-
gabalin.41 Tricyclic antidepressants, such as ami-
triptyline, are also occasionally used to treat 
chronic pruritus (e.g., neuropathic or psychogen-
ic forms),14,25 although these agents have not 
been studied for this use in randomized trials.
Opiate Agonists and Antagonists
Randomized, controlled trials have shown anti-
pruritic effects of mu-opioid antagonists (e.g., 
naltrexone, nalmefene, and naloxone) in patients 
with chronic urticaria, atopic eczema, and cho-
lestasis, findings that are consistent with the pre-
sumed involvement of endogenous activation of 
the mu-opioid receptor in mediating chronic itch 
(especially in systemic diseases such as chronic 
kidney disease and cholestasis).42 However, the 
results of studies of these agents for the treat-
ment of pruritus in patients with chronic kidney 
disease have been inconsistent.43,44 Their use is 
limited by initial adverse effects, such as nausea, 
loss of appetite, abdominal cramps, and diarrhea.
In randomized, placebo-controlled trials, nal-
fur a fine hydrochloride, a kappa-opioid agonist 
not currently available in the United States (but 
available in Japan), was shown to reduce itch sig-
nificantly in patients with chronic kidney dis-
ease.45,46 The major adverse effect is insomnia. 
According to anecdotal reports, butorphanol, a 
kappa-opioid agonist and mu-opioid antagonist 
that is administered intranasally and has been 
approved by the Food and Drug Administration for 
the treatment of migraine, reduces intractable 
itch associated with non-Hodgkin’s lymphoma, 
cholestasis, and opioid use.47
Phototherapy
Observational studies have suggested that broad- 
or narrow-band ultraviolet B (UVB) radiation, 
alone or combined with ultraviolet A (UVA) radia-
tion, reduces pruritus caused by chronic kidney 
disease and improves itch in skin diseases such 
as psoriasis, atopic eczema, and cutaneous T-cell 
lymphoma.48,49 In a single-blind, randomized trial 
involving patients with refractory itch caused by 
chronic kidney disease,50 there was no signifi-
cant difference in efficacy between narrow-band 
UVB radiation and UVA radiation.
Behavioral Therapy
Behavioral-modification therapies, including edu-
cation of the patient regarding coping mechanisms 
and stress-reduction techniques that interrupt the 
itch–scratch cycle, may complement pharmacother-
apy.51,52 However, data from randomized trials of 
such therapies are limited. In one randomized 
trial that assessed the addition of cognitive be-
havioral therapy and patient education to conven-
tional dermatologic therapy in patients with chron-
ic itch, there were short-term benefits in some 
outcomes, including a nonsignificant reduction 
in itch frequency and scratching (but not in inten-
sity) and significant improvement in the use of 
coping mechanisms.53
A r e a s of Uncerta in t y
The pathophysiology of pruritus is only partially 
understood. The optimal evaluation strategy with 
respect to yield and cost-effectiveness has not been 
determined. Data from randomized, controlled tri-
als of various pharmacologic and nonpharmaco-
logic treatments for chronic pruritus are scarce.
Guidelines
European guidelines for the management of 
chronic pruritus have been published. The rec-
ommendations in our article are largely concor-
dant with these guidelines, except that some 
medications are not currently available in the 
United States.25
Conclusions  
a nd R ecommendations
The patient described in the vignette presented 
with chronic, severe, generalized pruritus of un-
determined origin. He has prurigo nodules and 
lichenification (thickening of the skin); these are 
secondary to rubbing and scratching, not indica-
tive of a primary dermatologic condition. In such 
patients, careful examination is needed to look 
for a dermatologic disorder. A complete medical 
history should be taken, and a physical examina-
tion and basic laboratory tests should be per-
formed to look for evidence of systemic causes, 
such as chronic kidney disease, cholestasis, hyper-
thyroidism, or lymphoma. Periodic reevaluation 
is warranted if no cause is identified.
Since dryness of the skin may be subtle, and 
because dryness may aggravate pruritus of any 
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cause, emollients should be recommended; mild 
cleansers should be used to avoid further irrita-
tion. Trigger factors such as overheating from the 
use of excessive bedding should be avoided. Topi-
cal antipruritic agents (e.g., pramoxine) may be 
helpful.
In patients with severe pruritus that cannot be 
eliminated by identifying and treating an under-
lying cause (or pending effective primary treat-
ment), topical therapy and lifestyle changes are 
unlikely to be sufficient, and systemic therapy 
should be considered. Given a paucity of data 
from randomized trials to evaluate various ther-
apies, therapeutic choices are largely based on 
clinical experience and anecdotal reports. Sedat-
ing antihistamines are commonly used as first-
line therapy but often have only modest efficacy 
in practice (largely attributable to their soporific 
properties), and these drugs have not helped the 
patient described in the vignette. We would con-
sider off-label treatment with gabapentin, start-
ing at a low dose (e.g., 300 mg and increasing up 
to 2400 mg daily in divided doses). If this therapy 
is not adequate to control pruritus, we would con-
sider adding off-label treatment with low-dose 
mirtazapine (7.5 to 15.0 mg at night), although 
data from randomized trials are lacking to sup-
port this approach.
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